Immucell Corp /De/
ICCC Nasdaq· In Vitro & In Vivo Diagnostic Substances
Last close · Oct 26, 2026
$10.24
KIRA · Stoqly’s AI analyst, in plain words
- Immucell Corp /De/ had $27.6M of revenue in fiscal 2025, up 4.3% on the year before. Over five years, revenue changed +12.5% a year on average.
- Its operating margin was 6.0%, up 12.2 pts: of every 100 in sales, about 6 is left after running the business.
- Immucell Corp /De/ lost $1.0M in fiscal 2025.
- Free cash flow was $1.2M in fiscal 2025, 4.4% of revenue.
- Immucell Corp /De/ owes $5.3M more than it holds in cash, about 1.2 years of operating profit.
Market cap
$94.1M
P/E
146.3x
Revenue
$27.6M
Net income
−$1.0M
Free cash flow
$1.2M
Operating margin
6.0%
Immucell Corp /De/ in 30 seconds · fiscal 2025
Are sales growing?
+4.3%
Only a little. Sales grew 4.3% last year.
Does it make a profit?
−3.8%
No. It lost money last year.
Does profit turn into cash?
4.4%
Partly. 4.4% of sales ends up as free cash.
Is debt under control?
1.2x
Keep an eye on it. Repaying its debt would take 1.2 years of operating profit.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
146.3x
One share costs 146.3 times its yearly profit per share.
What Immucell Corp /De/ does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- IMMUCELL CORP /DE/
- CIK
- 0000811641
Immucell Corp /De/ · ICCC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $19.2M | $18.6M | $17.5M | $26.5M | $27.6M |
| Revenue growth | 25.4% | −3.5% | −5.9% | 51.6% | 4.3% |
| Gross margin | 45.0% | 41.2% | 22.1% | 30.0% | 41.4% |
| Operating margin | 1.3% | −12.4% | −32.9% | −6.2% | 6.0% |
| Net income | −$0.1M | −$2.5M | −$5.8M | −$2.2M | −$1.0M |
| Net margin | −0.4% | −13.4% | −33.1% | −8.1% | −3.8% |
| Diluted EPS | −$0.01 | −$0.32 | −$0.75 | −$0.26 | −$0.12 |
| Cash | |||||
| Cash from operations | $1.0M | −$1.5M | −$4.7M | $0.4M | $2.5M |
| Capital expenditure | $2.6M | $4.0M | $1.9M | $0.5M | $1.3M |
| Free cash flow | −$1.7M | −$5.5M | −$6.6M | −$0.1M | $1.2M |
| FCF margin | −8.6% | −29.7% | −37.6% | −0.4% | 4.4% |
| Share count change | 5.3% | 2.0% | 0.0% | 5.4% | 10.5% |
| Debt and strength | |||||
| Cash and short-term investments | $10.2M | $5.8M | $1.0M | $3.8M | $3.8M |
| Debt incl. finance leases | $0.8M | $19.1M | $22.4M | $10.5M | $9.1M |
| Shareholders' equity | $32.6M | $30.4M | $25.0M | $27.5M | $27.1M |
| Net debt / EBITDA | −3.5x | 78.6x | — | 6.2x | 1.2x |
| Current ratio | 6.4x | 4.6x | 2.7x | 3.4x | 4.3x |
| Interest coverage | 0.8x | −6.6x | −12.1x | −2.9x | 3.3x |
| Returns and quality | |||||
| Return on capital | 0.9% | −4.2% | −9.8% | −3.8% | 4.0% |
| Return on equity | −0.3% | −7.9% | −20.9% | −8.2% | −3.8% |
| Return on tangible equity | −0.2% | −8.3% | −23.2% | −7.9% | −3.9% |
| Piotroski F-score | 7 | 1 | 1 | 7 | 7 |
| Altman Z'' | 4.7 | 3.0 | 0.7 | 1.9 | 2.9 |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Immucell Corp /De/ · ICCC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $10.24 a share, the company is worth $94.1M: 146.3 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000811641). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.